William Pickering

what percent of the total enrollment was included in the submission? Did you have alignment with the FDA

Can you discuss how you see these combos fitting into the MG and GA treatment landscapes

if you could discuss how you expect the baseline GFR to impact the observed effect size

if you could discuss the competitive landscape in that indication and perhaps compared to IgAN

I was a little bit surprised to see that JOURNAVX was not included in the draft rule that was published

what are you seeing in terms of the cycle time from cell collection to infusion? And do you see potential for that to accelerate

What placebo effect did you assume in designing that study? And how does that compare to the 2 points placebo effect we saw in LSR